Tech Company Financing Transactions
EpiFrontier Therapeutics Funding Round
EpiFrontier Therapeutics closed a $32 million funding round on 3/24/2026. Investors included Japan Agency for Medical Research and Development (AMED).
Transaction Overview
Company Name
Announced On
3/24/2026
Transaction Type
Debt
Amount
$32,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to allocate the amount to clinical development of EPF-001, a novel small molecule G9a inhibitor designed to increase fetal hemoglobin expression in patients with sickle cell disease and beta thalassemia.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Pennington, NJ Undisclosed
USA
Pennington, NJ Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
EpiFrontier is developing a differentiated epigenetic modulator designed to safely and robustly increase fetal hemoglobin (HbF). Our lead program targets sickle cell disease, with planned expansion into other hemoglobinopathies, including ß-thalassemia. EpiFrontier is a biotechnology company developing oral therapies for hemoglobinopathies. Our goal is to deliver treatments that are accessible to patients worldwide, including those in regions with limited healthcare resources.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bruce Goldsmith
Chief Operating Officer
Ian Hardy
Browse more venture capital transactions:
Prev: 3/24/2026: NanoZymeX venture capital transaction
Next: 3/24/2026: Gilgamesh Pharmaceuticals venture capital transaction
Share this article
News on VC Transactions
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs